Amplification and Selection of Antimicrobial Resistance in the Intestine II
NCT ID: NCT03140826
Last Updated: 2020-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2018-01-30
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
NCT05791396
Amplification and Selection of Antimicrobial Resistance in the Intestine
NCT02058888
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
NCT04759001
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
NCT00752219
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)
NCT00389987
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meropenem arm
Patients receiving meropenem to treat an infection.
meropenem
Antibiotics to treat infections.
Pip-Tazo arm
Patients receiving piperacillin-meropenem to treat an infection.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
meropenem
Antibiotics to treat infections.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Need for treatment with meropenem or piperacillin-tazobactam
Exclusion Criteria
* HIV, HBV, HCV
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital of Cologne
OTHER
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Matthias Willmann
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias Willmann, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University Tuebingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Cologne
Cologne, , Germany
Institute of Medical Microbiology and Hygiene, University Hospital of Tuebingen
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASARI-II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.